News

The terms of the contract awarded by the Centers for Disease Control and Prevention (CDC), a unit of the US Department of Health and Human Services, were not

MedicAlert is making the Signature Genetics drug reaction test available to its members across the US with the help of Seryx. Terms of the agreement were not disclosed.

BLX-883 is the first clinical-stage therapeutic candidate produced in Biolex’ GMP facilities using its proprietary LEX system. In the phase I study BLX-883 was safely administered at a

The ongoing research is comparing the relative protection conveyed by Roche’s Tamiflu (oseltamivir) and Hemispherx’s Ampligen (dsRNA), alone and in combination, against the avian flu virus (H5N1). True

BAY 59-7939 (Factor Xa inhibitor) is currently undergoing phase II clinical trials. Phase III clinical trials to assess its effectiveness in the prevention of venous thromboembolism will also

HYB2055 (also known as IMO-2055 or IMOxine) is Idera’s lead toll-like receptor 9 (TLR9) agonist for the treatment of cancer. The phase I/II trial is a two-phase study

Diclofenac is marketed by Novartis as Cataflam/Voltaren and a topical diclofenac product is sold by SkyePharma under the brand name Solaraze. Formulations of topical diclofenac, a non-steroidal anti-inflammatory

Under the terms of the settlement agreement, Abbott will pay CAT $255 million, which CAT will pay to its licensors, the Medical Research Council (MRC), Scripps Institute and

The result follows the FDA’s acceptance of Insumed’s response to an approvable letter issued by the authority seeking further clarification. The submission is being made for iPlex, a